Alkermes’ (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
ALKS - Free Report) announced positive top-line data from a phase Ib study evaluating its novel, investigational, oral orexin 2 receptor (OX2R) agonist, ALKS 2680, as...
ALKS - Free Report) announced positive top-line data from a phase Ib study evaluating its novel, investigational, oral orexin 2 receptor (OX2R) agonist, ALKS 2680, as...